Temsirolimus – 10 mg

Brand:
Cayman
CAS:
162635-04-3
Storage:
-20
UN-No:
Non-Hazardous - /

Rapamycin (Item No. 13346) is an immunosuppressant that specifically interacts with the cytosolic FK-binding protein 12 to form a complex which inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding to mTOR Complex 1. Temsirolimus is a dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin.{22731} Treatment with temsirolimus leads to cell cycle arrest in the G1 phase and also inhibition of tumor angiogenesis by reducing synthesis of VEGF.{22733,22730} Temsirolimus demonstrates cytostatic activity in several xenograft models of human tumors in nude mice, including glioblastomas, prostate carcinoma, pancreatic, liver, and breast cancers, and medulloblastoma.{22733,22732,22730,22731}  

 

Available on backorder

SKU: 11590 - 10 mg Category:

Description

A dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin; demonstrates cytostatic activity in various mouse models of human tumors, including glioblastomas, prostate carcinoma, pancreatic, liver, breast cancers, and medulloblastoma


Formal name: 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate] rapamycin

Synonyms:  CCI-779|Torisel®

Molecular weight: 1,030.30

CAS: 162635-04-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling